Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: TomNY who wrote (133)	10/26/1998 4:01:00 PM
From: flickerful	Respond to of 2515

agreed.... i had a better entry last month, which i traded away... but in relative terms, i feel it is not too bad. i have also been impressed with the consistent support it has shown in the recent market malaise....notwithstanding the lack of speculation follow through, there has been no wholesale sell- off. sitting tight, as it were. flick

To: TomNY who wrote (133)	10/26/1998 9:12:00 PM
From: flickerful	Read Replies (1) \| Respond to of 2515

business week inside wall street 19 oct 98 IS IMCLONE STILL INCLINED TO DEAL? For weeks during the summer, shares of ImClone Systems (IMCL) had been hovering between 12 and 14, not only because the company has developed exciting anticancer products but because of rumors that a pact with a strategic partner was imminent. By late September, the hot money in the stock became impatient and bailed out. Result: ImClone plummeted, closing at a 1998 low of 5 15/16 on Oct. 6. Not so fast, says biotech maven Jim McCamant, editor of the Medical Technology Stock Letter in Berkeley, Calif. McCamant believes that a deal is in the works involving a European pharmaceutical company. McCamant, who thinks signing up a European partner is near, says this new partner will either take a significant equity stake in ImClone or license ImClone's lead compound, C225, now in Phase 3 clinical trials to treat head and neck cancer, such as mouth or throat cancer. ImClone is also conducting trials for C225 as a therapy for renal cell cancer. Another ImClone compound, BEC2, is a cancer vaccine that is being developed in collaboration with German drugmaker Merck KGaA (no relation to Merck & Co.). Also being developed are compounds to treat angiogenesis, which is the formation of new capillary blood vessels associated with tumors. ''ImClone's current market cap is unjustifiably low,'' says McCamant, who expects the stock to double once a partner is announced. BY GENE G. MARCIAL